文献速递前列腺癌

连续前列腺MRI检测主动监测期间前列腺癌进展的可靠性:系统综述与荟萃分析

Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol · 2021-05-19

该系统综述与荟萃分析纳入15项研究共2240例主动监测患者,评估连续前列腺MRI诊断前列腺癌进展的准确性。汇总敏感度0.59、特异度0.75,阴性预测值0.81–0.88,阳性预测值0.37–0.50。结论认为连续MRI单独不足以排除或确认进展。

要点

  • 连续前列腺MRI诊断进展的汇总敏感度0.59、特异度0.75,准确性有限。
  • 阴性预测值0.81–0.88,阳性预测值仅0.37–0.50。
  • PRECISE与机构自定义标准间敏感度(p=0.37)和特异度(p=0.74)无显著差异。

核心结论

  • 连续MRI不应作为排除主动监测期间前列腺癌进展的唯一依据,其变化不足以准确提示进展。

研究设计与样本

  • 系统检索PubMed、Scopus和Web of Science数据库,纳入分析连续前列腺MRI变化与主动监测期间前列腺癌进展关联的研究。
  • 共纳入15项研究、2240例患者,其中6项使用PRECISE标准,9项使用机构自定义MRI进展定义。

主要发现

  • 汇总前列腺癌进展率(含组织学进展至Gleason分级≥2)为27%。
  • 汇总敏感度为0.59(95%CI 0.44–0.73),汇总特异度为0.75(95%CI 0.66–0.84),研究间存在显著异质性。
  • 汇总阴性预测值随进展患病率范围为0.81(95%CI 0.73–0.88)至0.88(95%CI 0.83–0.93),汇总阳性预测值范围为0.37(95%CI 0.24–0.54)至0.50(95%CI 0.36–0.66)。
  • PRECISE与机构自定义方案的汇总敏感度(p=0.37)和特异度(p=0.74)无显著差异。

关键数值与推荐

  • 汇总敏感度0.59(95%CI 0.44–0.73),汇总特异度0.75(95%CI 0.66–0.84)。
  • 汇总阴性预测值0.81(95%CI 0.73–0.88)至0.88(95%CI 0.83–0.93),汇总阳性预测值0.37(95%CI 0.24–0.54)至0.50(95%CI 0.36–0.66)。
  • PRECISE与机构自定义方案敏感度比较p=0.37,特异度比较p=0.74。

临床怎么用

  • 连续MRI结果需结合其他临床因素和生物标志物综合判断,不应单独用于决定是否排除进展或触发活检。
  • 应进一步明确主动监测期间活检的最佳触发因素和时机,并优化连续前列腺MRI的质量、判读与报告。

局限性

  • 纳入研究间存在显著异质性。
  • MRI进展定义不一致,部分使用PRECISE标准,部分使用机构自定义定义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although magnetic resonance imaging (MRI) is broadly implemented into active surveillance (AS) protocols, data on the reliability of serial MRI in order to help guide follow-up biopsy are inconclusive. OBJECTIVE: To assess the diagnostic estimates of serial prostate MRI for prostate cancer (PCa) progression during AS. EVIDENCE ACQUISITION: We systematically searched PubMed, Scopus, and Web of Science databases to select studies analyzing the association between changes on serial prostate MRI and PCa progression during AS. We included studies that provided data for MRI progression, which allowed us to calculate diagnostic estimates. We compared Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) accuracy with institution-specific definitions. EVIDENCE SYNTHESIS: We included 15 studies with 2240 patients. Six used PRECISE criteria and nine institution-specific definitions of MRI progression. The pooled PCa progression rate, which included histological progression to Gleason grade ≥2, was 27%. The pooled sensitivity and specificity were 0.59 (95% confidence interval [CI] 0.44-0.73) and 0.75 (95% CI 0.66-0.84) respectively. There was significant heterogeneity between included studies. Depending on PCa progression prevalence, the pooled negative predictive value for serial prostate MRI ranged from 0.81 (95% CI 0.73-0.88) to 0.88 (95% CI 0.83-0.93) and the pooled positive predictive value ranged from 0.37 (95% CI 0.24-0.54) to 0.50 (95% CI 0.36-0.66). There were no significant differences in the pooled sensitivity (p = 0.37) and specificity (p = 0.74) of PRECISE and institution-specific schemes. CONCLUSIONS: Serial MRI still should not be considered a sole factor for excluding PCa progression during AS, and changes on MRI are not accurate enough to indicate PCa progression. There was a nonsignificant trend toward improved diagnostic estimates of PRECISE recommendations. These findings highlight the need to further define the optimal triggers and timing of biopsy during AS, as well as the need for optimizing the quality, interpretation, and reporting of serial prostate MRI. PATIENT SUMMARY: Our study suggests that serial prostate magnetic resonance imaging (MRI) alone in patients on active surveillance is not accurate enough to reliably rule out or rule in prostate cancer progression. Other clinical factors and biomarkers along with serial MRI are required to safely tailor the intensity of follow-up biopsies.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Rajwa P, Pradere B, Quhal F, et al. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. Eur Urol. 2021. PMID: 34020828. doi:10.1016/j.eururo.2021.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。